-
公开(公告)号：US11643464B2
公开(公告)日：2023-05-09
申请号：US16728587
申请日：2019-12-27
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61P27/02 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K31/4155 , A61K33/36 , A61K39/00
CPC classification number: C07K16/2818 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K39/395 , A61K39/39541 , A61K45/06 , C07K16/2803 , C07K16/2827 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/572 , C07K2317/21 , C07K2317/24 , C07K2317/76 , A61K33/36 , A61K2300/00 , A61K31/404 , A61K2300/00 , A61K31/4155 , A61K2300/00 , A61K31/7068 , A61K2300/00
Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
2.发明申请公开(公告)号：US20200332011A1
公开(公告)日：2020-10-22
申请号：US16852508
申请日：2020-04-19
Inventor： Ester Yoles , Berit Olsen Krogh , Allan Jensen , Jan Egebjerg , Carol David , Kuti Baruch , Michal Eisenbach-Schwartz
IPC: C07K16/28
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
-
3.发明申请公开(公告)号：US20190185563A1
公开(公告)日：2019-06-20
申请号：US16284081
申请日：2019-02-25
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K38/02 , A61K38/00 , A61K31/4155 , A61K38/16 , A61K38/18 , A61K38/20 , A61K38/14 , A61K45/06 , A61K31/404 , A61K39/395 , A61K33/36 , A61K31/7068
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
公开(公告)号：US20180111999A1
公开(公告)日：2018-04-26
申请号：US15821678
申请日：2017-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K45/06 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/02 , A61K38/14 , A61K38/16 , A61K38/18 , A61K38/20 , A61K31/404 , A61K39/395 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
5.发明申请公开(公告)号：US20180111998A1
公开(公告)日：2018-04-26
申请号：US15821672
申请日：2017-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K45/06 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/14 , A61K38/16 , A61K38/18 , A61K31/404 , A61K39/395 , A61K38/20 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
Patent Agency Ranking
公开(公告)号：US11884727B2
公开(公告)日：2024-01-30
申请号：US17186960
申请日：2021-02-26
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61P25/28 , A61P37/02 , A61K38/00 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K38/16 , A61K38/18 , A61K38/20 , A61K31/4155 , A61K38/02 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/3955 , A61K39/39541 , A61K45/06 , C07K16/2818 , C07K16/2827 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K38/208 , A61K2300/00 , A61K33/36 , A61K2300/00 , A61K31/404 , A61K2300/00 , A61K31/4155 , A61K2300/00 , A61K31/7068 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
7.发明公开公开(公告)号：US20230183350A1
公开(公告)日：2023-06-15
申请号：US17806187
申请日：2022-06-09
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K31/4155 , A61K31/7068 , A61K31/404 , A61K33/36 , A61K45/06 , A61P25/16 , A61P37/06 , A61P25/28 , A61P27/02
CPC classification number: C07K16/2827 , C07K16/2818 , C07K16/2803 , A61K39/3955 , A61K31/4155 , A61K39/395 , A61K39/39541 , A61K31/7068 , A61K31/404 , A61K33/36 , A61K45/06 , A61P25/16 , A61P37/06 , A61P25/28 , A61P27/02 , A61K2039/545
Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
公开(公告)号：US09982051B2
公开(公告)日：2018-05-29
申请号：US15821678
申请日：2017-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K31/7068 , A61K38/00 , A61K38/18 , A61K38/16 , A61K38/02 , A61K45/06 , A61K31/4155 , A61K38/14 , A61K38/20 , A61K33/36 , A61K31/404 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
9.发明授权公开(公告)号：US09982050B2
公开(公告)日：2018-05-29
申请号：US15821672
申请日：2017-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K38/16 , A61K31/7068 , A61K45/06 , A61K38/18 , A61K38/14 , A61K38/00 , A61K38/20 , A61K33/36 , A61K31/404 , A61K31/4155 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
10.发明授权公开(公告)号：US09982048B2
公开(公告)日：2018-05-29
申请号：US15821595
申请日：2017-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K38/16 , A61K31/7068 , A61K45/06 , A61K38/18 , A61K38/14 , A61K38/00 , A61K38/20 , A61K33/36 , A61K31/404 , A61K31/4155 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
-
-
-
-
-
-
-
-
Search Results
43
records
(took 0.03 seconds)
